Effect of Antidepressant Switching Vs Augmentation on Remission Among Patients with Major Depressive Disorder Unresponsive to An

Total Page:16

File Type:pdf, Size:1020Kb

Effect of Antidepressant Switching Vs Augmentation on Remission Among Patients with Major Depressive Disorder Unresponsive to An VA Cooperative Studies Program #576 VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) STUDY PROTOCOL Version 5.2 March 9, 2015 Co-Principal Proponents: Somaia Mohamed, M.D., Ph.D. Sidney Zisook, M.D. Biostatistician: Gary R. Johnson, M.S. PRIVILEGED AND CONFIDENTIAL Not For Distribution Beyond the Intended Committee Function Downloaded From: https://jamanetwork.com/ on 09/23/2021 [THIS PAGE LEFT INTENTIONALLY BLANK] Downloaded From: https://jamanetwork.com/ on 09/23/2021 Table of Contents Page LETTERS OF SUBMITTAL: ....................................................................................................... 1 A. Principal Proponents ................................................................................................................. 1 B. Acting Director: Cooperative Studies Program Center, West Haven .................................. 3 C. Cooperative Studies Program Clinical Research Pharmacy Coordinating Center ............... 5 EXECUTIVE SUMMARY ......................................................................................................... 11 PLANNING COMMITTEE ........................................................................................................ 15 I. INTRODUCTION AND BACKGROUND ............................................................................ 17 A. Introduction ....................................................................................................................... 17 B. Study Rationale ................................................................................................................. 18 C. Goals of Treatment: Achieving and Maintaining Remission ............................................ 20 D. Why BUP-SR? .................................................................................................................. 24 E. Why aripiprazole? ............................................................................................................. 26 F. Summary ........................................................................................................................... 29 II. PRELIMINARY RESEARCH .............................................................................................. 30 III. STUDY OBJECTIVES ......................................................................................................... 31 A. Primary Objectives ............................................................................................................ 31 B. Secondary Objectives ........................................................................................................ 31 C. Tertiary (Other) Objectives ............................................................................................... 33 IV. STUDY OUTCOME MEASURES .................................................................................. 34 A. Primary Outcome .............................................................................................................. 34 B. Secondary Outcomes ......................................................................................................... 36 C. Additional Outcomes ......................................................................................................... 39 V. SUMMARY OF STUDY DESIGN AND METHODS ......................................................... 41 A. Background and Significance ............................................................................................ 41 B. Study Population ............................................................................................................... 42 C. Treatment Regimens ......................................................................................................... 43 D. Outcome Measures ............................................................................................................ 44 E. Sample Size ....................................................................................................................... 45 F. Study Monitoring .............................................................................................................. 45 VI. RATIONALE FOR OVERALL DESIGN CONSIDERATIONS ......................................... 47 VII. PATIENT POPULATION ................................................................................................ 48 A. Inclusion Criteria ............................................................................................................... 48 B. Exclusion Criteria .............................................................................................................. 48 C. Rationale for Participant Selection .................................................................................... 49 D. Definition and Rationale for “Adequate Treatment Trial” of Index Antidepressant ......... 51 VIII. PATIENT RECRUITMENT AND SCREENING ............................................................ 55 CSP#576 (VAST-D) Protocol Version 5.2 i 03/09/2015 Downloaded From: https://jamanetwork.com/ on 09/23/2021 IX. HUMAN RIGHTS ISSUES AND INFORMED CONSENT ................................................ 57 A. Consent Procedure............................................................................................................. 57 B. Surrogate Consent ............................................................................................................. 58 C. Risks and Benefits ............................................................................................................. 59 D. Informed Consent .............................................................................................................. 59 E. Certificate of Confidentiality ............................................................................................. 59 X. BASELINE ASSESSMENT.................................................................................................. 60 XI. STRATIFICATION AND RANDOMIZATION .................................................................. 62 XII. BLINDING OF THE RANDOMIZATION SCHEME ..................................................... 64 XIII. FOLLOW-UP ASSESSMENT PROCEDURES .............................................................. 65 A. Assessments administered at each visit ............................................................................. 65 B. Assessments administered at baseline, at the end of acute treatment (12 weeks or sooner), at 24 weeks, and at the end of study (36 weeks or sooner) only ...................................... 66 XIV. TREATMENT REGIMENS ............................................................................................. 67 A. General Principles ............................................................................................................. 67 B. Acute Treatment ................................................................................................................ 68 C. Continuation Treatment ..................................................................................................... 72 D. Concomitant Medications and Treatments ........................................................................ 79 XV. DISCONTINUATION OF TREATMENT ....................................................................... 82 XVI. METHODS TO MAXIMIZE ADHERENCE ................................................................... 84 XVII. MONITORING ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS (SAE)... 84 A. Suicide-Related Risks Monitoring .................................................................................... 84 B. Role of the Local Site Investigator in Adverse Event Monitoring .................................... 88 C. Definitions ......................................................................................................................... 88 D. Adverse Events and Serious Adverse Events to be Documented ...................................... 89 E. Adverse Event and Serious Adverse Event Monitoring .................................................... 90 F. Expedited Reporting of Serious Adverse Events to CSP .................................................. 90 G. Reporting of Serious Related and Unexpected Events ...................................................... 91 H. Reporting of Adverse and Serious Adverse Events to the DMC ....................................... 91 I. Reporting Requirements of the VA Central IRB ............................................................... 91 XVIII. COST EFFECTIVENESS ............................................................................................. 92 A. Overview and Perspective ................................................................................................. 92 B. Costs and Other Economic Measures ................................................................................ 93 C. Cost-Effectiveness Analysis .............................................................................................. 95 D. Analysis of Other Economic Outcomes ............................................................................ 97 E. Inflation and Discounting .................................................................................................. 97 F. Sensitivity Analysis ........................................................................................................... 97 XIX. LIMITATIONS OF THE PROTOCOL ...........................................................................
Recommended publications
  • Aripiprazole As an Adjunct to Anti-Depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-Effectiveness, and Guidelines
    TITLE: Aripiprazole as an Adjunct to Anti-Depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-Effectiveness, and Guidelines DATE: 04 May 2016 RESEARCH QUESTIONS 1. What is the clinical efficacy of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? 2. What is the cost-effectiveness of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? 3. What are the evidence-based guidelines for the use of aripiprazole for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? KEY FINDINGS Three systematic reviews with meta-analyses, two randomized controlled trials, and two evidence-based guidelines were identified regarding the use of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments. METHODS A limited literature search was conducted on key resources including PubMed, Ovid PsychINFO, Ovid Embase, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were used to limit retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2014 and April 29, 2016. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada.
    [Show full text]
  • Antidepressant Discontinuation Syndrome CHRISTOPHER H
    Antidepressant Discontinuation Syndrome CHRISTOPHER H. WARNER, MAJ, MC, USA, Winn Army Community Hospital, Fort Stewart, Georgia WILLIAM BOBO, LCDR, MC, USN, Uniformed Services University of the Health Sciences, Bethesda, Maryland CAROLYNN WARNER, MAJ, MC, USA, Winn Army Community Hospital, Fort Stewart, Georgia SARA REID, CPT, USAF, MC, Bolling Air Force Base, Washington, D.C. JAMES RACHAL, MAJ, USAF, MC, Ehrling Berquist Air Force Hospital, Offutt Air Force Base, Omaha, Nebraska Antidepressant discontinuation syndrome occurs in approximately 20 percent of patients after abrupt discontinuation of an antidepressant medication that was taken for at least six weeks. Typical symptoms of antidepressant discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal. These symptoms usu- ally are mild, last one to two weeks, and are rapidly extinguished with reinstitution of antide- pressant medication. Antidepressant discontinuation syndrome is more likely with a longer duration of treatment and a shorter half-life of the treatment drug. A high index of suspicion should be maintained for the emergence of discontinuation symptoms, which should prompt close questioning regarding accidental or purposeful self-discontinuation of medication. Before antidepressants are prescribed, patient education should include warnings about the potential problems associated with abrupt discontinuation. Education about this common and likely underrecognized clinical phenomenon will help prevent future episodes
    [Show full text]
  • A Novel Atypical Antidepressant That May Provide New Insights Into the Biomolecular Basis of Depression
    Recent Patents on CNS Drug Discovery, 2006, 1, 29-41 29 Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression Christiaan B. Brink*, Brian H. Harvey and Linda Brand Division of Pharmacology, North-West University (PUK), Potchefstroom, 2520, South Africa Received: July 29, 2005; Accepted: September 05, 2005; Revised: September 12, 2005 Abstract: Tianeptine, an atypical antidepressant patented and developed by Servier, enhances the synaptic reuptake of serotonin, without affecting norepinephrine and dopamine uptake, while it lacks affinity for neurotransmitter receptors. This mechanism for an antidepressant is apparently paradoxical, since the currently employed antidepressants enhance serotonin by inhibiting its breakdown or by inhibiting monoaminergic reuptake. Although tianeptine has been shown to reduce central 5HT availability and to indirecty modulate central adrenergic and dopaminergic systems and to indirectly inhibit cholinergic hyperactivity, its antidepressant action is believed to be more directly related to central neuronal remodeling and restoration of neuronal plasticity. In reliable animal models of depression tianeptine has been shown to prevent neurodegeneration and decreases in hippocampal volume in response to chronic stress. These effects on neuroplasticity are suspected to involve the normalization of the hypothalamic-pituitary-adrenal axis and modulatory effects on excitatory amino acids and N-methyl-D-aspartate receptors. Together with a body of related studies, these data provide further support for the hypothesis that depression may involve dysregulation of pathways controlling cellular resilience and that treatment should be directed towards the reversal thereof. Importantly, tianeptine is not anxiogenic and has also been shown to be effective in treatment-resistant depression, which may lead the way to a major breakthrough in the treatment of depression.
    [Show full text]
  • Download Executive Summary
    Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Effective Health Care Program Antipsychotics medications are approved The Effective Health Care Program by the U.S. Food and Drug Administration was initiated in 2005 to provide valid (FDA) for treatment of schizophrenia and evidence about the comparative bipolar disorder. These medications are effectiveness of different medical commonly divided into two classes, interventions. The object is to help reflecting two waves of historical consumers, health care providers, and development: the conventional others in making informed choices antipsychotics and the atypical. The among treatment alternatives. Through conventional antipsychotics served as the its Comparative Effectiveness Reviews, first successful pharmacologic treatment the program supports systematic for primary psychotic disorders such as appraisals of existing scientific schizophrenia. Having been widely used evidence regarding treatments for for decades, the conventional high-priority health conditions. It also antipsychotics also produced various side promotes and generates new scientific effects requiring additional medications, evidence by identifying gaps in which spurred the development of the existing scientific evidence and atypical antipsychotics. supporting new research. The program Currently, nine atypical antipsychotic drugs puts special emphasis on translating have been approved by FDA: aripiprazole, findings into a variety of useful asenapine, clozapine, iloperidone, formats for different stakeholders, olanzapine, paliperidone, quetiapine, including consumers. risperidone, and ziprasidone. These drugs The full report and this summary are have been used off-label (i.e., for available at www.effectivehealthcare. indications not approved by FDA) for the ahrq.gov/reports/final.cfm. treatment of various psychiatric conditions.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson Et Al
    US006319953B1 (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson et al. (45) Date of Patent: *Nov. 20, 2001 (54) TREATMENT OF DEPRESSION AND WO 95/08549 3/1995 (W0). ANXIETY WITH FLUOXETINE AND AN WO 95/18124 7/1995 (W0). NK-1 RECEPTOR ANTAGONIST W0 96/05181 2/1996 (W0). W0 96/18643 6/1996 (W0). (75) Inventors: Emma Joanne Carlson, Puckeridge; W0 96/19233 6/1996 (W0). Nadia Melanie Rupniak, Bishops W0 96/24353 8/1996 (W0). W0 98/15277 4/1998 (W0). Stortford, both of (GB) OTHER PUBLICATIONS (73) Assignee: Merck Sharp & Dohme Ltd., Hoddesdon (GB) Aguiar, M., et al., Physiology& Behavior, 1996, 60(4) 1183—1186. ( * ) Notice: Subject to any disclaimer, the term of this Barden, N., et al., J. Neurochem., 1983, 41, 834—840. patent is extended or adjusted under 35 BristoW, L., et al., Eur J. Pharmacol., 1994, 253, 245—252. U.S.C. 154(b) by 0 days. Brodin, E., et al., Neuropharmacology, 1987, 26(6) 581—590. This patent is subject to a terminal dis Brodin, E., et al., Neuropeptides, 1994, 26, 253—260. claimer. Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885—891. Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87. (21) Appl. N0.: 09/457,241 Elliott, P. J., Exp. Brain Res. UK, 1988, 73, 354—356. (22) Filed: Dec. 8, 1999 F—D—C Reports—Prescription Pharmaceuticals and Bio technology, Dec. 8, 1997, 59(49), 10. Related US. Application Data File, S. E., Pharm. Biochem. Behavior, 1997, 58, 3, 747—752. (60) Division of application No.
    [Show full text]
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]
  • Journal of Psychiatry
    Soares et al., J Psychiatry 2014, 17:6 Journal of Psychiatry http://dx.doi.org/10.4172/1994-8220.1000160 Research Article Open Access Depression and Cognitive Decline: Factors Related to Demographics and Psycho Pharmacotherapy on Elderly in Nursing Homes Edvaldo Soares1* and Patrícia de Souza Rossignoli2 1,2Sao Paulo State University, Laboratory of Cognitive Neuroscience-LaNeC *Corresponding author: Edvaldo Soares, Sao Paulo State University, Av. Hygino Muzzi Filho, 737,Marília, São Paulo, Brazil. CEP: 17500-090; Tel: 551434021371; E-mail: [email protected] Received Date: May 5, 2014, Accepted Date: September 23, 2014, Published Date: September 30, 2014 Copyright: © 2014, Edvaldo Soares et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Objectives: To identify the prevalence of neuropsychiatric disorders, especially DP and CD, on a sample of nursing home residents, relating this prevalence with some aspects of the demographics and psycho pharmacotherapy. Methods: 48 elders from two different nursing homes were selected. The collection of demographic and pharmacological data was made utilizing medical records. The medication was classified according to the Anatomical Therapeutic Chemical Code (ATC) criteria. The Geriatric Depression Scale (GDS 30) and the Mini Mental State Examination (MMSE) tests were utilized to determine the prevalence of DP and CD. Results: It was observed in the sample a high incidence of DP and CD among the researched elders. More schooling individuals tend to present less CD. Individuals with less CD indicatives present less symptomatology for DP.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Second-Generation Long-Acting Injectable Antipsychotics: a PRACTICAL GUIDE Understanding Each of These Medications’ Unique Properties Can Optimize Patient Care
    Second-generation long-acting injectable antipsychotics: A PRACTICAL GUIDE Understanding each of these medications’ unique properties can optimize patient care Brittany L. Parmentier, PharmD, MPH, here are currently 7 FDA-approved second-generation long-acting BCPS, BCPP 1-7 Clinical Assistant Professor injectable antipsychotics (LAIAs). These LAIAs provide a Department of Pharmacy Practice Tunique dosage form that allows patients to receive an antipsy- The University of Texas at Tyler Fisch College of Pharmacy chotic without taking oral medications every day, or multiple times per Tyler, Texas day. This may be an appealing option for patients and clinicians, but Disclosure The author reports no financial relationships with any because there are several types of LAIAs available, it may be difficult to companies whose products are mentioned in this article, or with determine which LAIA characteristics are best for a given patient. manufacturers of competing products. Since the FDA approved the first second-generation LAIA, risperidone long-acting injectable (LAI),1 in 2003, 6 additional second-generation LAIAs have been approved: • aripiprazole LAI • aripiprazole lauroxil LAI • olanzapine pamoate LAI • paliperidone palmitate monthly injection • paliperidone palmitate 3-month LAI • risperidone LAI for subcutaneous (SQ) injection. When discussing medication options with patients, clinicians need to consider factors that are unique to each LAIA. In this article, I describe the similarities and differences among the second-generation LAIAs, and address common questions about these medications. A major potential benefit: Increased adherence One potential benefit of all LAIAs is increased medication adherence com- pared with oral antipsychotics. One meta-analysis of 21 randomized con- trolled trials (RCTs) that compared LAIAs with oral antipsychotics and Current Psychiatry GEORGE MATTEI/SCIENCE SOURCE GEORGE MATTEI/SCIENCE Vol.
    [Show full text]
  • Efficacy and Tolerability of Aripiprazole Versus D2 Antagonists in the Early
    www.nature.com/npjschz REVIEW ARTICLE OPEN Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis David D. Kim1,2, Alasdair M. Barr1,2, Lulu Lian1, Jessica W. Y. Yuen1, Diane Fredrikson3, William G. Honer2,3, Allen E. Thornton2,4 and ✉ Ric M. Procyshyn 2,3 Early intervention is essential for favorable long-term outcomes in schizophrenia. However, there is limited guidance in the scientific literature on how best to choose between dopamine D2 receptor (D2R) partial agonists and D2R antagonists in early stages of schizophrenia. The aim of this meta-analysis was to directly compare D2R partial agonists with D2R antagonists for efficacy and tolerability, using randomized controlled trials (RCTs) that involved participants diagnosed with first-episode psychosis, schizophrenia, or related psychotic disorders with a duration of illness ≤5 years. Fourteen RCTs, involving 2494 patients, were included in the meta-analysis. Aripiprazole was the only identified D2R partial agonist, and was not significantly different from pooled D2R antagonists for overall symptom reduction or all-cause discontinuation. However, aripiprazole was more favorable than pooled D2R antagonists for depressive symptoms, prolactin levels, and triglyceride levels. Specifically, aripiprazole was more favorable than paliperidone for triglyceride levels and more favorable than risperidone and olanzapine, but less favorable than ziprasidone, for weight gain. In addition, aripiprazole was less favorable for akathisia compared with second-generation D2R 1234567890():,; antagonists, in particular olanzapine and quetiapine, and less favorable for discontinuation due to inefficacy than risperidone. Lastly, aripiprazole was more favorable than haloperidol for various efficacy and tolerability outcomes.
    [Show full text]
  • Aripiprazole Lauroxil
    PATIENT & CAREGIVER EDUCATION Aripiprazole Lauroxil This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Aristada; Aristada Initio Warning There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia. What is this drug used for? It is used to treat schizophrenia. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to aripiprazole or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you take any drugs (prescription or OTC, natural products, vitamins) that must not be taken with this drug, like certain drugs that are used for seizures, fungal infections, or rifampin. There are many drugs that must not be taken with this drug. Aripiprazole Lauroxil 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems.
    [Show full text]
  • Aristada Initio (Aripiprazole Lauroxil), in Combination with Oral Aripiprazole for the Initiation of Aristada When Used for the Treatment of Schizophrenia in Adults
    Aristada Initio™ (aripiprazole lauroxil) – New drug approval • On July 2, 2018, Alkermes announced the FDA approval of Aristada Initio (aripiprazole lauroxil), in combination with oral aripiprazole for the initiation of Aristada when used for the treatment of schizophrenia in adults. — The approval of Aristada Initio provides physicians with an alternative regimen to initiate patients onto any dose of Aristada injection on day 1. — Previously, the first Aristada injection was recommended in conjunction with oral aripiprazole for 21 consecutive days. • Oral aripiprazole is generically available as tablets, disintegrating tablets, and solution. Aripiprazole is also available as Abilify Maintena®, a brand extended-release injectable suspension. — The oral formulations are approved for the treatment of schizophrenia and other indications as outlined in the individual drug labels. — Abilify Maintena is indicated for the treatment of schizophrenia in adults and as maintenance monotherapy treatment of bipolar I disorder in adults. • Aristada Initio leverages Alkermes’ proprietary NanoCrystal® technology, which provides an extended-release formulation using a smaller particle size compared to Aristada, thereby enabling faster dissolution and more rapid achievement of relevant drug levels. • The effectiveness of Aristada Initio, in combination with oral aripiprazole and for the initiation of Aristada injection, was established by adequate and well-controlled studies of oral aripiprazole and Aristada injection in adult patients with schizophrenia.
    [Show full text]